Flourish Research, a clinical trial company and a portfolio company of NMS Capital, has recapitalized and partnered with Keystone Clinical Studies LLC, a clinical research site focused on Alzheimer’s Disease and other conditions related to the central nervous system.

Headquartered in Plymouth Meeting, Penn., Keystone focuses on Alzheimer’s Disease and other neurodegenerative conditions. In recent years, the company has gained market share in the greater Philedelphia area. Cherian Verghese has spent over 30 years conducting clinical research and will help with Flourish’s future strategy in the therapeutic area. Verghese and the current management team will continue in their roles leading Keystone after the acquisition.

“The Keystone partnership was exactly what we were looking for in terms of entering a new market in Philadelphia as well as expanding our CNS capabilities, which is one of Flourish’s focus areas,” states Reinhold Schulz, CEO of Flourish Research. “I am excited to continue growing Flourish into a national market leader within the clinical research site space.”

Quadriga served as financial advisor and Royer Cooper Cohen Braunfeld LLC provided legal advice to Keystone.  Cantor Fitzgerald & Co. served as financial advisor and McDermott Will & Emery provided legal advice to Flourish and NMS.